No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KNSA Kiniksa Pharmaceuticals
- 17.400
- -0.040-0.23%
Trading Apr 16 15:48 ET
1.23BMarket Cap87.00P/E (TTM)
17.610High17.330Low185.60KVolume17.380Open17.440Pre Close3.24MTurnover0.59%Turnover Ratio87.00P/E (Static)70.62MShares22.09052wk High2.80P/B549.94MFloat Cap10.64552wk Low--Dividend TTM31.61MShs Float32.880Historical High--Div YieldTTM1.61%Amplitude5.010Historical Low17.477Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Kiniksa Pharmaceuticals (KNSA) Receives a Buy From Goldman Sachs
Kiniksa Pharmaceuticals Advances Clinical Trials and Ensures Positive Cash Flow
World's First Pig-to-human Kidney Transplant Performed in U.S
Kiniksa Pharmaceuticals(KNSA.US) Officer Sells US$1.37 Million in Common Stocks
$Kiniksa Pharmaceuticals(KNSA.US)$ Officer Patel Sanj K sold 65,012 shares of Common Stocks on Mar 7, 2024 at an average price of $21.02 for a total value of $1.37 million.Source: Announcement What is
Kiniksa Pharmaceuticals(KNSA.US) Officer Sells US$391.06K in Common Stocks
$Kiniksa Pharmaceuticals(KNSA.US)$ Officer Patel Sanj K sold 18,324 shares of Common Stocks on Mar 4, 6, 2024 at an average price of $21.34 for a total value of $391.06K.Source: Announcement What is s
Kiniksa Pharmaceuticals(KNSA.US) Officer Sells US$410.23K in Common Stocks
$Kiniksa Pharmaceuticals(KNSA.US)$ Officer Paolini John F. sold 18,844 shares of Common Stocks on Mar 1, 2024 at an average price of $21.77 for a total value of $410.23K.Source: Announcement What is s
Comments
The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week AloneKiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.
Upcoming Ph 2 readouts in Q1 2024…
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg